Our results also suggest that in the PBMC of ADCTA group, although high counts of PD1+, CD4+, or CD8+ T-cells and high counts of PD-1+, but CD4− and CD8− lymphoid cells (including CD4 and CD8 double-negative T-cells) are identified, not all of these cells can reach the GBM tumor site and effect the ability of tumor killing by T-cells. This evidence concerns the gene CD8A and neoplasm.